Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Get the Most Familiar Drive for Seniors in SUVs - 2Trouvez La Carte De Cr\u00e9dit Id\u00e9ale Pour Vos Besoins En Belgique
- 3From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- 4Amazon sued over 'punitive' handling of employee absences
- 5Manual for 6 famous sorts of cheddar
- German mid-sized firms gloomy on outlook, survey finds
- A Manual for the Right SUV for Seniors
- The Quadrantid meteor shower peaks tonight, but will the full 'Wolf Moon' outshine the show?
- Green Inflections: A Manual for Inside Plants
- Shrewd Home Gadgets to Save Energy
- 6 Famous Urban communities for Shopping on the planet
- New dietary guidelines recommend more dairy, meat and fats: What to know
- 7 Extraordinary Efficiency Applications for Experts
- Extreme Manual for Purchasing Your Next Truck
